文献速递骨肿瘤

低深度全基因组测序液体活检能否检测肉瘤患者的循环肿瘤DNA?一项初步评估

Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation.
PubMed 文献 · Clin Orthop Relat Res · 2024-06-21

这项回顾性初步研究在社区三级转诊中心,用低深度全基因组测序(LP-WGS)分析13例肉瘤患者血浆和3例无癌对照的血浆游离DNA,通过ichorCNA算法检测拷贝数改变(CNA)。结果在13例肉瘤患者中的9例血浆标本中检测到循环肿瘤DNA(ctDNA),4例肉瘤患者及所有无癌对照均未检出。

要点

  • LP-WGS液体活检在13例肉瘤患者中的9例血浆标本中检出ctDNA。
  • 9例阳性患者ctDNA占cfDNA比例为6%至11%,ctDNA浓度为0.04至5.6 ng/mL。
  • 4例肉瘤患者及全部无癌对照血清标本均未检出ctDNA。

核心结论

  • 在这项小型初步研究中,采用LP-WGS液体活检寻找CNA,可在多数组织学亚型多样的肉瘤患者血浆中检测到肉瘤ctDNA。
  • 这些结果提示,评估CNA以识别ctDNA的LP-WGS液体活检可能比既往针对特定亚型的研究更广泛地适用于肉瘤患者群体。
  • 需要大型前瞻性临床试验在诊断、治疗和监测过程中多时间点采集样本来进一步评估该技术是否有临床用途。

研究设计与样本

  • 本研究为在社区三级转诊中心开展的回顾性研究,标本来自商业生物样本库。
  • 研究纳入9对(血浆和福尔马林固定石蜡包埋组织)及4份非配对(血浆)肉瘤患者标本,另取3份无癌个体对照标本。
  • 血浆游离DNA经提取、扩增和定量后,使用NextSeq 500二代测序仪以约1×的低深度测序覆盖度进行LP-WGS。
  • 使用ichorCNA生物信息学算法分析数据以检测CNA,并定量估算ctDNA占cfDNA的百分比。
  • 配对FFPE组织与血浆样本的CNA使用aCNViewer软件进行图形化展示。

主要发现

  • LP-WGS液体活检在13份肉瘤患者血浆标本中的9份中检测到ctDNA。
  • 其余4份肉瘤患者标本及所有无癌对照血清标本均未检测到ctDNA。
  • 9例液体活检阳性患者中,ctDNA占cfDNA百分比范围为6%至11%,计算出的ctDNA量为0.04至5.6 ng/mL。

关键数值与推荐

  • 若ichorCNA算法检测到ctDNA存在,则液体活检判定为癌症阳性。
  • ctDNA浓度由ctDNA占cfDNA百分比相对于cfDNA总浓度计算得出。
  • 该检测不区分肉瘤亚型,而是检测血液ctDNA中肿瘤来源的CNA,这些CNA在无癌患者中不应存在。

临床怎么用

  • 作者认为,评估CNA以识别ctDNA的LP-WGS液体活检可能比既往针对特定亚型的研究更广泛地适用于肉瘤患者群体。
  • 作者指出,需要大型前瞻性临床试验在诊断、治疗和监测过程中多时间点采集样本来进一步评估该技术是否有临床用途。
  • 本研究中心正在为此目的筹备一项大型前瞻性临床试验。

局限性

  • 这是一项小型初步研究。
  • 本研究为回顾性研究。
  • 需要大型前瞻性临床试验在诊断、治疗和监测过程中多时间点采集样本来进一步评估该技术是否有临床用途。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: A liquid biopsy is a test that evaluates the status of a disease by analyzing a sample of bodily fluid, most commonly blood. In recent years, there has been progress in the development and clinical application of liquid biopsy methods to identify blood-based, tumor-specific biomarkers for many cancer types. However, the implementation of these technologies to aid in the treatment of patients who have a sarcoma remains behind other fields of cancer medicine. For this study, we chose to evaluate a sarcoma liquid biopsy based on circulating tumor DNA (ctDNA). All human beings have normal cell-free DNA (cfDNA) circulating in the blood. In contrast with cfDNA, ctDNA is genetic material present in the blood stream that is derived from a tumor. ctDNA carries the unique genomic fingerprint of the tumor with changes that are not present in normal circulating cfDNA. A successful ctDNA liquid biopsy must be able to target these tumor-specific genetic alterations. For instance, epidermal growth factor receptor (EGFR) mutations are common in lung cancers, and ctDNA liquid biopsies are currently in clinical use to evaluate the status of disease in patients who have a lung cancer by detecting EGFR mutations in the blood. As opposed to many carcinomas, sarcomas do not have common recurrent mutations that could serve as the foundation to a ctDNA liquid biopsy. However, many sarcomas have structural changes to their chromosomes, including gains and losses of portions or entire chromosomes, known as copy number alterations (CNAs), that could serve as a target for a ctDNA liquid biopsy. Murine double minute 2 (MDM2) amplification in select lipomatous tumors or parosteal osteosarcoma is an example of a CNA due to the presence of extra copies of a segment of the long arm of chromosome 12. Since a majority of sarcomas demonstrate a complex karyotype with numerous CNAs, a blood-based liquid biopsy strategy that searches for these CNAs may be able to detect the presence of sarcoma ctDNA. Whole-genome sequencing (WGS) is a next-generation sequencing technique that evaluates the entire genome. The depth of coverage of WGS refers to how detailed the sequencing is, like higher versus lower power on a microscope. WGS can be performed with high-depth sequencing (that is, > 60×), which can detect individual point mutations, or low-depth sequencing (that is, 0.1× to 5×), referred to as low-passage whole-genome sequencing (LP-WGS), which may not detect individual mutations but can detect structural chromosomal changes including gains and losses (that is, CNAs). While similar strategies have shown favorable early results for specific sarcoma subtypes, LP-WGS has not been evaluated for applicability to the broader population of patients who have a sarcoma. QUESTIONS/PURPOSES: Does an LP-WGS liquid biopsy evaluating for CNAs detect ctDNA in plasma samples from patients who have sarcomas representing a variety of histologic subtypes? METHODS: This was a retrospective study conducted at a community-based, tertiary referral center. Nine paired (plasma and formalin-fixed paraffin-embedded [FFPE] tissue) and four unpaired (plasma) specimens from patients who had a sarcoma were obtained from a commercial biospecimen bank. Three control specimens from individuals who did not have cancer were also obtained. The paired and unpaired specimens from patients who had a sarcoma represented a variety of sarcoma histologic subtypes. cfDNA was extracted, amplified, and quantified. Libraries were prepared, and LP-WGS was performed using a NextSeq 500 next-generation sequencing machine at a low depth of sequencing coverage (∼1×). The ichorCNA bioinformatics algorithm, which was designed to detect CNAs from low-depth genomic sequencing data, was used to analyze the data. In contrast with the gold standard for diagnosis in the form of histopathologic analysis of a tissue sample, this test does not discriminate between sarcoma subtypes but detects the presence of tumor-derived CNAs within the ctDNA in the blood that should not be present in a patient who does not have cancer. The liquid biopsy was positive for the detection of cancer if the ichorCNA algorithm detected the presence of ctDNA. The algorithm was also used to quantitatively estimate the percent ctDNA within the cfDNA. The concentration of ctDNA was then calculated from the percent ctDNA relative to the total concentration of cfDNA. The CNAs of the paired FFPE tissue and plasma samples were graphically visualized using aCNViewer software. RESULTS: This LP-WGS liquid biopsy detected ctDNA in 9 of 13 of the plasma specimens from patients with a sarcoma. The other four samples from patients with a sarcoma and all serum specimens from patients without cancer had no detectable ctDNA. Of those 9 patients with positive liquid biopsy results, the percent ctDNA ranged from 6% to 11%, and calculated ctDNA quantities were 0.04 to 5.6 ng/mL, which are levels to be expected when ctDNA is detectable. CONCLUSION: In this small pilot study, we were able to detect sarcoma ctDNA with an LP-WGS liquid biopsy searching for CNAs in the plasma of most patients who had a sarcoma representing a variety of histologic subtypes. CLINICAL RELEVANCE: These results suggest that an LP-WGS liquid biopsy evaluating for CNAs to identify ctDNA may be more broadly applicable to the population of patients who have a sarcoma than previously reported in studies focusing on specific subtypes. Large prospective clinical trials that gather samples at multiple time points during the process of diagnosis, treatment, and surveillance will be needed to further assess whether this technique can be clinically useful. At our institution, we are in the process of developing a large prospective clinical trial for this purpose.

来源:Clin Orthop Relat Res,查看原文。版权归原作者所有。

引用

  1. Anderson CJ, Yang H, Parsons J, et al. Can a Liquid Biopsy Detect Circulating Tumor DNA With Low-passage Whole-genome Sequencing in Patients With a Sarcoma? A Pilot Evaluation. Clin Orthop Relat Res. 2024. PMID: 38905450. doi:10.1097/CORR.0000000000003161

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。